Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

T vs. C	sunitinib	atezolizumab plus bevacizumab	avelumab plus axitinib	pembrolizumab plus axitinib	nivolumab plus ipilimumab	nivolumab plus cabozantinib	atezolizumab alone	pembrolizumab plus lenvatinib	lenvatinib plus everolimus	lenvatinib in association
sunitinib	---	1.11 0.94; 1.31	1.38 1.19; 1.60	1.89 1.35; 2.63	1.46 1.16; 1.85	1.67 1.12; 2.49	NA	1.52 1.13; 2.03	0.87 0.67; 1.14	NA
atezolizumab plus bevacizumab	0.90 0.76; 1.07	---	1.24 0.99; 1.56	1.70 1.17; 2.47	1.32 0.99; 1.76	1.50 0.97; 2.32	NA	1.37 0.97; 1.92	0.78 0.57; 1.08	NA
avelumab plus axitinib	0.73 0.63; 0.84	0.80 0.64; 1.01	---	1.37 0.95; 1.97	1.06 0.80; 1.40	1.21 0.79; 1.85	NA	1.10 0.79; 1.53	0.63 0.46; 0.86	NA
pembrolizumab plus axitinib	0.53 0.38; 0.74	0.59 0.40; 0.85	0.73 0.51; 1.05	---	0.78 0.52; 1.17	0.88 0.52; 1.49	NA	0.80 0.52; 1.25	0.46 0.30; 0.71	NA
nivolumab plus ipilimumab	0.68 0.54; 0.86	0.76 0.57; 1.01	0.94 0.71; 1.24	1.29 0.86; 1.94	---	1.14 0.72; 1.81	NA	1.03 0.71; 1.51	0.59 0.42; 0.85	NA
nivolumab plus cabozantinib	0.60 0.40; 0.89	0.67 0.43; 1.03	0.83 0.54; 1.27	1.13 0.67; 1.91	0.88 0.55; 1.40	---	NA	0.91 0.55; 1.49	0.52 0.32; 0.84	NA
atezolizumab alone	NA	NA	NA	NA	NA	NA	---	NA	NA	NA
pembrolizumab plus lenvatinib	0.66 0.49; 0.88	0.73 0.52; 1.03	0.91 0.66; 1.26	1.25 0.80; 1.94	0.97 0.66; 1.41	1.10 0.67; 1.81	NA	---	0.57 0.39; 0.85	NA
lenvatinib plus everolimus	1.15 0.88; 1.50	1.28 0.93; 1.75	1.59 1.17; 2.15	2.17 1.42; 3.32	1.68 1.18; 2.40	1.92 1.19; 3.10	NA	1.74 1.17; 2.59	---	NA
lenvatinib in association	NA	NA	NA	NA	NA	NA	NA	NA	NA	---

pathologies: 79,178,152 - treatments: 1477 result logic